Guggenheim Raises Johnson & Johnson (JNJ) Target on Icotyde Upside, Keeps Buy Rating

Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Dow Stocks to Invest in Now.

Guggenheim Raises Johnson & Johnson (JNJ) Target on Icotyde Upside, Keeps Buy Rating

On April 20, Guggenheim Partners raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $266 from $244. It reiterated a Buy rating on the shares. The firm updated its model after the company’s Q1 earnings and took a closer look at the Icotyde opportunity following its approval in plaque psoriasis last month. It now sees higher potential from the drug, raising its unadjusted peak revenue estimate to $14.9 billion from about $10 billion, the analyst noted.

During the Q1 2026 earnings call, Vice President of Investor Relations Darren Snellgrove said worldwide sales reached $24.1 billion for the quarter. He also reported net earnings of $5.2 billion, with diluted EPS at $2.14 and adjusted diluted EPS at $2.70.

Executive Vice President and CFO Joseph Wolk said the company ended the quarter with around $22 billion in cash and marketable securities, along with $55 billion in debt. He added that free cash flow came in at about $1.5 billion for the quarter. The board also approved a 3.1% increase in the annual dividend, bringing it to $5.36 per share.

Johnson & Johnson (NYSE:JNJ) operates across the healthcare sector, focusing on the research, development, manufacturing, and sale of a wide range of products. Its business is organized into two segments: Innovative Medicine and MedTech.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Reddit Stocks That Will Skyrocket and 12 High Dividend Stocks Picked By Billionaire Ray Dalio

Disclosure: None. Follow Insider Monkey on Google News.